Evidence Level:Sensitive: C3 – Early Trials
New
Title:
Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated MGMT gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial
Excerpt:...we embarked on a Phase II clinical trial in which CPZ has been added to the standard disease treatment....The RACTAC schedule showed an overall clinical benefit in GBM patients carrying hypo-/un-methylated MGMT gene promoter. When compared with historical cohorts, these patients displayed longer PFS...
DOI:https://doi.org/10.1101/2023.02.21.23286088